logowsbdaily | Thu, 21 Oct 2021 07:34:40 EST Where you find Tomorrow’s Hot Stocks Yesterday! 

NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.

CRISPR Therapeutics AG
(CRSP)

CRISPR Therapeutics AG
Baarerstrasse 14
Zug, 6300
Switzerland
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and r... Read More

Summary & Charts

Price$ 98.37-1.89 (-1.89%)
Day's Range$ 98.28 - 101.74 
Previous Close$ 100.26
Market Cap$ 9.47B USD
Short Interest %7.27 %As of Wed, 31 Mar 2021
Float61.39M
Outstanding75.61M
ExchangeNasdaqGS
IndustryBiotechnology
SectorHealthcare
Volume1.19M
Avg. Volume (20 day)1.68M
Rel. Volume (20 day)0.70
Rel. Volume (3 month)0.96
RatingA+Strong Buy
DCFN/AStrong Buy
Debt/Equity11.36 %Neutral
ROE24.08 %Buy
ROA15.40 %Buy
P/E16.66 %Buy
P/B2.86 %Strong Buy
DateOpenHighLowCloseChangeVolumeR. Vol. (20d)R. Vol. (3m)Mentions
Oct 20, 2021$ 100.50$ 101.74$ 98.28$ 98.37-1.891,185,9560.700.963
Oct 19, 2021$ 97.47$ 102.96$ 97.34$ 100.26+4.051,928,9401.161.564
Oct 18, 2021$ 97.34$ 97.47$ 95.68$ 96.21-0.791,269,8560.791.046
Oct 15, 2021$ 99.23$ 99.81$ 96.65$ 97.00-1.701,858,8001.151.5318
Oct 14, 2021$ 98.35$ 102.64$ 96.60$ 98.70+1.932,910,1141.812.424
Oct 13, 2021$ 92.80$ 98.33$ 92.33$ 96.77-5.826,427,0224.295.4027
Oct 12, 2021$ 101.25$ 104.79$ 100.63$ 102.59+1.941,321,9701.091.1722
Oct 11, 2021$ 99.05$ 101.34$ 98.68$ 100.65+2.021,803,1181.521.515
Oct 08, 2021$ 102.79$ 102.91$ 96.55$ 98.63-4.363,476,8632.992.807
Oct 07, 2021$ 102.50$ 105.53$ 101.66$ 102.99+1.00909,8080.890.753
Oct 06, 2021$ 101.82$ 103.77$ 99.10$ 101.99-0.501,180,6301.160.974
Oct 05, 2021$ 102.98$ 105.60$ 101.77$ 102.49+0.06955,7590.950.791
Oct 04, 2021$ 110.00$ 110.01$ 102.23$ 102.43-8.861,766,6241.771.451
Oct 01, 2021$ 111.75$ 112.39$ 108.94$ 111.29-0.64915,0080.950.76
Sep 30, 2021$ 111.36$ 114.18$ 110.45$ 111.93+1.73733,3800.770.61
Sep 29, 2021$ 112.54$ 113.95$ 109.63$ 110.20-1.951,122,4641.160.921
Sep 28, 2021$ 115.57$ 115.78$ 111.88$ 112.15-5.111,274,4291.341.042
Sep 27, 2021$ 116.17$ 117.84$ 113.50$ 117.26+0.83773,0030.850.631
Sep 24, 2021$ 119.51$ 120.24$ 116.01$ 116.43-4.821,086,0711.190.892
Sep 23, 2021$ 119.26$ 122.25$ 116.91$ 121.25+3.44775,7690.860.632

News

The latest news about CRISPR Therapeutics AG (CRSP).

The Motley Fool | 2021-10-20 06:10:00
The company's value isn't reflected in typical performance metrics.
24/7 Wall Street | 2021-10-19 15:18:14
Another day of strong earnings is pushing the broad markets higher across the board.
The Motley Fool | 2021-10-16 07:00:00
These two novel-drug makers could be top takeover targets next year.
Seeking Alpha | 2021-10-15 03:27:16
CRISPR Therapeutics was down at one point 10% after hours following reports of poorer than expected efficacy levels for its CTX110 CAR-T cell therapy. CRISPR is currently (55%) off all-time highs set at the beginning of 2021.
Zacks Investment Research | 2021-10-14 12:38:56
Here we discuss four biotech companies, CRSP, EDIT, SRPT and BEAM, that have the potential to gain from their promising gene therapy pipeline candidates.
24/7 Wall Street | 2021-10-14 09:41:38
A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday.
GlobeNewsWire | 2021-10-14 07:00:00
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Brendan Smith as Chief Financial Officer, effective today. Mr. Smith brings more than 20 years of financial, operational and strategic leadership experience, including as CFO of Translate Bio. He succeeds Michael Tomsicek, who is retiring after four years of service to the Company. It is expected that Mr. Tomsicek will remain with the Company in an advisory role through the end of 2021 to help ensure a smooth transition.

Earnings

DateTimeEPS ExpectedEPS Reported%Revenue ExpectedRevenue Reported%
2021-10-26BMO-1.76----1.2M----
2021-07-29BMO4.199.44125.29%421M0.9B113.98%
2021-04-27BMO-1.47-1.512.72%1.2M0.5M-55.46%
2021-02-16BMO-1.27-1.5018.11%2.5M370K-85.2%
2020-10-28BMO-1.18-1.3211.86%132K148K11.86%
2020-07-27BMO-0.95-1.3036.84%32K44K36.84%
2020-04-28BMO-1.05-1.159.52%143K157K9.52%
2020-02-12BMO-0.630.51180.96%95M77M-19.05%

Top Discussions

These are the top discussions over the last 24-hours that mention the CRSP stock ticker symbol.


Failures to Deliver

Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.

Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.

Last Updated: Tue, 13 Jul 2021 12:00 EST


Support & Feedback

Got feedback or suggestions for more awesomeness? Or wanna keep up to date with changes?

@wsbdaily@wsbdailywsbdaily subredditwsbdaily

No obligation, if you'd like to support us with development and hosting costs then

Buy Me A Coffee

Disclaimer

WE ARE NOT AFFILIATED WITH REDDIT, THE LEADERSHIP OR MODERATOR TEAMS OF ANY OF THE SUBREDDITS WE CRAWL NOR WITH ANY OTHER WEBSITE, COMPANY OR DATA PROVIDER FROM WHICH WE PULL AND/OR AGGREGATE DATA FROM.

ALL CONTENT ON THIS SITE IS SOLEY FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY. THE SITE AND CONTENT, ARE PROVIDED “AS IS” AND WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED. ANY CONTENT OR STATEMENT HEREIN SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, OR AS AN OFFER TO BUY, SELL, OR SOLICIT THE PURCHASE OR SALE OF ANY SECURITY OR FINANCIAL INSTRUMENT. DO YOUR OWN DUE DILIGENCE.

THE INFORMATION ON THIS SITE IS NOT UPDATED IN REAL-TIME, EACH DATASET SPECIFIES WHEN IT WAS “LAST UPDATED”. MOST INFORMATION IS CURRENTLY INDEPENDENTLY PERIODICALLY UPDATED EVERY 30 TO 150 MINUTES AND ONLY WHEN THE MARKETS ARE CLOSED. YOU BEAR ALL RISKS ASSOCIATED WITH THE USE OF THE SITE AND CONTENT, INCLUDING WITHOUT LIMITATION, ANY RELIANCE ON THE ACCURACY, COMPLETENESS OR USEFULNESS OF ANY CONTENT AVAILABLE ON THE SITE. YOUR USE OF THE INFORMATION CONTAINED HEREIN IS SOLELY AT YOUR OWN RISK. DO YOUR OWN DUE DILIGENCE.

There are high risks associated with investing in securities. Investing in stocks, options, bonds, ETFs, mutual funds, and money market funds involve risk of substantial loss. Loss of principal is possible. Some high risk investments may use leverage, which will greatly accentuate any losses. Foreign investing involves special risks, including a greater volatility and political, economic and currency risks and differences in accounting methods. Any past investment performance is not a guarantee or predictor of future investment performance. DO YOUR OWN DUE DILIGENCE.

The software providing the content on this site is currently in an alpha state. Although care is taken to publish accurate data inaccurate information is very, very possible. Use at your own risk. DO YOUR OWN DUE DILIGENCE.